Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents


CAPITALIZATION

        The following table sets forth our cash, cash equivalents and marketable securities and our capitalization as of June 30, 2014, as follows:

    on an actual basis;
    on a pro forma basis to give effect to the automatic preferred stock conversion; and
    on a pro forma as adjusted basis to give further effect to the issuance and sale of                shares of our common stock by us and the receipt of the estimated net proceeds from such sale, assuming an initial public offering price of $            per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated expenses payable by us.

        You should read this table together with our financial statements and the related notes appearing at the end of this prospectus and "Selected Financial Data" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included elsewhere in this prospectus.

 
  As of June 30, 2014  
 
  Actual   Pro Forma   Pro Forma
as Adjusted
 
 
  (in thousands, except share and per share data)
(unaudited)

 

Notes payable, including current portion

  $ 7,505   $ 7,505   $    

Series A-1 noncumulative convertible preferred stock, par value $0.0001: 675,000 shares authorized, 675,000 issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted

    675                   

Series A-2 noncumulative convertible preferred stock, par value $0.0001: 16,575,000 shares authorized, 16,500,000 issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted

    16,379                   

Series B noncumulative convertible preferred stock, par value $0.0001: 151,812,780 shares authorized, 151,112,779 issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted

    63,964                   

Series C noncumulative convertible preferred stock, par value $0.0001: 16,700,007 shares authorized, 16,666,673 issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted

    14,937                   

Series D noncumulative convertible preferred stock, par value $0.0001: 26,012,500 shares authorized, 25,000,000 issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted

    29,915                   

Stockholders' (deficit) equity:

   
 
   
 
   
 
 

Preferred stock, $0.0001 par value, no shares authorized, no shares issued and outstanding, actual;              shares authorized, no shares issued and outstanding, pro forma and pro forma as adjusted

                   

Common stock, par value $0.0001: 312,825,000 shares authorized, 14,111,936 shares issued and outstanding, actual; 312,825,000 shares authorized, 232,421,677 shares issued and outstanding, pro forma;              shares authorized and              shares issued and outstanding, pro forma as adjusted

    1     23               

Additional paid-in capital

    4,132     129,980               

Accumulated comprehensive loss

    (1 )   (1 )             

Accumulated deficit

    (120,896 )   (120,896 )             
               

Total stockholders' (deficit) equity

    (116,764 )   9,106               
               

Total capitalization

  $ 16,611   $ 16,611               
               
               

        The pro forma as adjusted information below is illustrative only and our cash and cash equivalents and capitalization following the closing of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed initial public offering price of $            per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) each of cash and cash equivalents, additional paid-in capital, total stockholders' (deficit) equity and total capitalization by $             million, assuming

48